Orforglipron (Capsules)

Non-Peptide Oral GLP-1 Receptor Agonist

CAS: 2212020-52-3

Formula: C₄₀H₄₇F₃N₈O₅

M.W.: 776.8549 g/mol

Purity: 99%+ HPLC Verified

Ref No.: ORF-0006TA

For Research Use Only (RUO)

Not for human or veterinary use.

COA Included With Every Order

Third-Party Lab Tested

Cold-Chain Packaging Included

Quality Guaranteed

Free Shipping on Orders $150+

99%+ HPLC Verified Purity

Orforglipron (Capsules)

Name: Orforglipron (Capsules)
SKU: orforglipron-capsule
Availability: InStock

Category

GLP / Metabolic

CAS Number

2212020-52-3

Form Factor

Capsules

Select mg:

6 mg (60 ct)

Clear

BUNDLE & SAVE

Quantity:

FREE Shipping on orders $150+ (after any discounts)

In stock, ready to ship

Ships same day before 12pm PST

Products are shipped in freeze dried powder form.

Orforglipron is a first-in-class non-peptide, oral GLP-1 receptor agonist — achieving GLP-1 receptor activation through a small molecule rather than a peptide. Phase II data showed dose-dependent weight reduction up to 14.7% over 36 weeks with once-daily dosing and room-temperature stability.

CAS Number

2212020-52-3

Purity

99%+ HPLC Verified

Molecular Formula

C₄₀H₄₇F₃N₈O₅

Molar Mass

776.8549 g/mol

Form Factor

Capsules

Synonyms

LY3502970 Non-Peptide Oral GLP-1

Pharmaceutical Sciences: Orforglipron represents a paradigm shift as a first-in-class non-peptide, oral GLP-1 receptor agonist — achieving GLP-1 receptor activation through a small molecule rather than a peptide. Research examines its binding mode, receptor activation kinetics, and biased agonism profile compared to peptide GLP-1 agonists. Studies investigate whether small-molecule agonism produces qualitatively different downstream signaling and clinical outcomes.
Metabolic Research: Orforglipron capsules are studied for oral incretin therapy in obesity and type 2 diabetes. Phase II clinical data showed dose-dependent weight reduction up to 14.7% over 36 weeks with once-daily dosing. Research examines glycemic control, appetite suppression, and metabolic improvement kinetics to optimize dosing strategies for different metabolic disease severities.
Drug Delivery: Orforglipron is studied for its room-temperature stability and oral bioavailability — significant advantages over injectable peptide GLP-1 agonists that require refrigeration and subcutaneous administration. Research examines the pharmacokinetic profile of oral administration, food-effect studies, and the potential for improved patient compliance with daily oral versus weekly injectable treatment regimens.
Clinical Pharmacology: Orforglipron is studied for dose-response optimization in weight reduction and glycemic control endpoints. Research examines the relationship between plasma drug levels, receptor occupancy, and clinical efficacy across different dose levels. Studies investigate whether oral GLP-1 agonism can achieve comparable efficacy to injectable peptide agonists while offering the convenience of oral administration.

Reconstitution Protocol

1 Remove the flip-off cap and wipe the rubber stopper with an alcohol swab.
2 Using a sterile syringe, draw the desired volume of bacteriostatic water (BAC water).
3 Insert the needle into the vial at an angle and slowly dispense the water down the inside wall — do not spray directly onto the powder.
4 Gently swirl (do not shake) the vial until the powder is fully dissolved.
5 Label the vial with the reconstitution date and concentration.

Storage Conditions

Unreconstituted

Store at -20°C to 4°C (freezer or refrigerator). Stable for 24+ months.

Reconstituted

Refrigerate at 2–8°C. Use within 30 days for optimal stability.

Avoid

Repeated freeze-thaw cycles, direct sunlight, and temperatures above 25°C.

Always note the reconstitution date on the vial label to track shelf life accurately.

Safety & Compliance

Wear nitrile gloves and safety goggles when handling research compounds.
Work in a clean, controlled environment (laminar flow hood recommended).
Dispose of sharps and used materials in approved biohazard containers.
This product is for laboratory research use only (RUO) — not for human or veterinary use.